ENUM Low Float DD pack — Plant News
ENUM Low Float DD pack: ENUM is developing two antagonist PD-1 antibodies, such as ENUM 388D4 (more can be read on ENUM 388D4 here)and ENUM 244C8 for use in treating cancer. The company is also developing antibody drug candidates for various immunomodulatory protein targets, including TIM-3, CD39, and TIGIT. Enumeral Biomedical Holdings, Inc. has collaboration agreements with Merck Sharp & Dohme Corp.; and The University of Texas MD Anderson Cancer Center, as well as a research contract with the National Cancer Institute. Other drug listings here. The number of new cases of cancer (cancer incidence) is 454.8 per 100,000 men and women per year (based on 2008-2012 cases). The number of cancer deaths (cancer mortality) is 171.2 per 100,000 men and women per year (based on 2008-2012 deaths). Which can be read here. Corporate Overview Enumeral is in the process of developing novel antibody immunothrapies that help the imune system attack diseased cells. Enumeral’s exquisite platform allows them to identify and characterize promising new drug relvant to cancer, infectious and inflammatory diseases, Giving them the potential to positively affect millions of patients whom are underserved by the current therapeutic alternatives. The core technology behind their platform was developed and licensed [...]